Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | KIT | P10721 | 9/20 | 0.41 |
| ▸ | PDE2A | O00408 | 2/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.36 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 2/20 | 0.35 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4866766 | 0.82 | PIK3CD (0.36) | CYP2A6 | |
| SCHEMBL4863385 | 0.81 | LOXL2 (0.44) | LOXL2KITPDE2APIK3CACYP2A6 | |
| SCHEMBL4870527 | 0.79 | LMNA (0.39) | PDE2A | |
| SCHEMBL4861236 | 0.77 | LOXL2 (0.42) | LOXL2PIK3CACYP2A6MKNK1MKNK2 | |
| SCHEMBL5674893 | 0.76 | NPY5R (0.53) | CYP2A6 | |
| SCHEMBL6428383 | 0.72 | TLR8 (0.40) | — | |
| SCHEMBL6014373 | 0.70 | HRH1 (0.45) | LOXL2CYP2A6 | |
| SCHEMBL14269015 | 0.69 | PIK3CA (0.39) | LOXL2PIK3CACYP2A6MKNK1MKNK2 | |
| SCHEMBL1696482 | 0.68 | PIK3CA (0.41) | PIK3CAMKNK1MKNK2MTOR | |
| SCHEMBL4866713 | 0.66 | CYP19A1 (0.42) | PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7163924-B2 | Ketolide derivatives | CHIRON CORPORATION (US) | 2007-01-16 | — | — | US | claimed |
| US-20050153905-A1 | Novel ketolide derivatives | CHIRON CORPORATION (US) | 2005-07-14 | — | — | US | claimed |
| US-7332476-B2 | Pyridyl substituted ketolide antibiotics | NOVARTIS AG (CH) | 2008-02-19 | — | — | US | disclosed |
| US-7163924-B2 | Ketolide derivatives | CHIRON CORPORATION (US) | 2007-01-16 | — | — | US | disclosed |
| EP-1618120-A2 | NOVEL KETOLIDE DERIVATIVES | CHIRON CORPORATION (US) | 2006-01-25 | — | — | EP | disclosed |
| EP-1618119-A2 | PYRIDYL SUBSTITUTED KETOLIDE ANTIBIOTICS | CHIRON CORPORATION (US) | 2006-01-25 | — | — | EP | disclosed |
| US-20050153905-A1 | Novel ketolide derivatives | CHIRON CORPORATION (US) | 2005-07-14 | — | — | US | disclosed |
| US-20050009764-A1 | Pyridyl substituted ketolide antibiotics | CHIRON CORPORATION (US) | 2005-01-13 | — | — | US | disclosed |
| WO-2004096822-A2 | PYRIDYL SUBSTITUTED KETOLIDE ANTIBIOTICS | CHIRON CORPORATION (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096823-A2 | NOVEL KETOLIDE DERIVATIVES | CHIRON CORPORATION (US) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009764-A1 | Pyridyl substituted ketolide antibiotics | PKLR, KHK, PGD | LOXL2 1023/4885KIT 2190/4885PDE2A 1580/4885 |
| US-20050153905-A1 | Novel ketolide derivatives | KHK, CYP51A1, SI | LOXL2 1976/4885KIT 1717/4885PDE2A 1617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.